Sodium-glucose co-transporter-2 inhibitor-associated non-diabetic ketoacidosis: a case report

Published: 4 April 2024
Abstract Views: 292
PDF: 239
HTML: 54
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Ketoacidosis is considered an emergency metabolic disorder that can be triggered by starvation and alcohol consumption in addition to diabetes. We described an unusual case of ketoacidosis in a non-diabetic young man who presented to our hospital with a complaint of rapid and shallow breathing, weakness and nausea. Fourteen days back, due to heart failure, he started sodiumglucose co-transporter 2 inhibitors (SGLT2-i) in addition to fumarate bisoprolol, sacubitril/valsartan and eplerenone. Based on clinical examination, ketoacidosis was suspected, although his glucose and glycosylated hemoglobin levels were in range. Overall, based on the clinical and laboratory findings, the diagnosis of euglycemic non-diabetic ketoacidosis due to the use of the SGLT2- i was made and SGLT2-i has been discontinued. Although SGLT2-i are effective and safe drugs, it is advisable to carefully evaluate their use also in non-diabetic patients especially when hepatic fibrosis or incorrect eating habits are present.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Salvatore T, Carbonara O, Cozzolino D, et al. Kidney in diabetes: From organ damage target to therapeutic target. Curr Drug Metab 2011;12:658-66. DOI: https://doi.org/10.2174/138920011796504509
Salvatore T, Galiero R, Caturano A, et al. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int J Mol Sci 2022;23:3651. DOI: https://doi.org/10.3390/ijms23073651
Van Bommel EJ, Muskiet MH, Tonneijck L, et al. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. Clin. J Am Soc Nephrol 2017;12:700-10. DOI: https://doi.org/10.2215/CJN.06080616
Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation 2016;134:752-72. DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.021887
Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016;7:135-8. DOI: https://doi.org/10.1111/jdi.12401
Kelley JL, Strum M, Riche DM, Chandler AM. Sodium Glucose Transporter 2 Inhibitors and Diabetic Ketoacidosis in Three Patients with Diabetes: Underlying Causation. J Pharmacol Pharmacother 2017;8:137-9.
Mahfooz RS, Khan MK, Al Hennawi H, Khedr A. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review. Cureus 14:e26267.
Bashir B, Fahmy AA, Raza F, Banerjee M. Non-diabetic ketoacidosis: a case series and literature review. Postgrad Med J 2021;97:667-71. DOI: https://doi.org/10.1136/postgradmedj-2020-138513
Sloan G, Ali A, Webster J. A rare cause of metabolic acidosis: ketoacidosis in a non-diabetic lactating woman. Endocrinol Diabetes Metab Case Rep 2017;2017:17-0073. DOI: https://doi.org/10.1530/EDM-17-0073
Howard RD, Bokhari SRA. Alcoholic ketoacidosis (AKA). StatPearls 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430922/ (updated May 22nd, 2020)
Ghimire P, Dhamoon AS. Ketoacidosis. StatPearls 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534848/ (updated August 8th, 2023)
Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 2017;136:1643-58. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.030012
Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annu Rev Physiol 2021;83:503-28. DOI: https://doi.org/10.1146/annurev-physiol-031620-095920
Owen OE, Reichle FA, Mozzoli MA, et al. Hepatic, Gut, and Renal Substrate Flux Rates in Patients with Hepatic Cirrhosis. J Clin Investig 1981;68:240-52. DOI: https://doi.org/10.1172/JCI110240
Chandrasekara H, Fernando P, Danjuma M, et al. Ketoacidosis is not always due to diabetes. BMJ Case Rep 2014;2014:bcr2013203263. DOI: https://doi.org/10.1136/bcr-2013-203263

How to Cite

Trapanese, V., Maruca, F., Natale, M. R., Giofrè, F., Cosentino, F., Sergi, S., Armentaro, G., Condoleo, V., & Arturi, F. (2024). Sodium-glucose co-transporter-2 inhibitor-associated non-diabetic ketoacidosis: a case report. Italian Journal of Medicine, 18(2). https://doi.org/10.4081/itjm.2024.1716